---
document_datetime: 2025-05-13 16:52:51
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/clopidogrel-krka-dd-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: clopidogrel-krka-dd-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.1513788
conversion_datetime: 2025-12-27 14:06:58.260188
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Clopidogrel Krka d.d.

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Article 61(3) /      | - Notification acc. Article 61(3) - | 13/05/2025                          |                                             | PL                               |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000267861   | Update of the package leaflet with revised contact details of local representative and deletion of 'United Kingdom (Northern Ireland)' from the list of local representatives in line with the QRD template v10.4.   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|